EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 (Novembre 2019) Hors série n° 2 Med Sci (Paris), 35 (2019) 18-23 References
Free Access
Issue
Med Sci (Paris)
Volume 35, Novembre 2019
Les Cahiers de Myologie
Page(s) 18 - 23
Section Mise au point
DOI https://doi.org/10.1051/medsci/2019178
Published online 20 December 2019
  1. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep 2018; 20: 28. [CrossRef] [PubMed] [Google Scholar]
  2. Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 2017; 84: 55–64. [CrossRef] [PubMed] [Google Scholar]
  3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum (Hoboken, NJ) 2017; 69: 2271–82. [Google Scholar]
  4. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337–45. [CrossRef] [PubMed] [Google Scholar]
  5. Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018; 75: 1528–37. [Google Scholar]
  6. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–7. [Google Scholar]
  7. Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976; 5: 12–20. [PubMed] [Google Scholar]
  8. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360–74. [CrossRef] [PubMed] [Google Scholar]
  9. Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 2019; 18: 293–305. [Google Scholar]
  10. Hengstman GJD, Vree Egberts WTM, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65: 242–5. [CrossRef] [PubMed] [Google Scholar]
  11. Landon-Cardinal O, Monseau G, Schoindre Y, et al. Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy [abstract]. Arthritis . Rheumatol 2016; 68 (Suppl 10). Accessed July 20, 2017. [Google Scholar]
  12. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, et al. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42: 1448–54. [CrossRef] [PubMed] [Google Scholar]
  13. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–9. [CrossRef] [PubMed] [Google Scholar]
  14. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513–22. [CrossRef] [PubMed] [Google Scholar]
  15. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015; 72: 449–55. [CrossRef] [PubMed] [Google Scholar]
  16. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523–32. [CrossRef] [PubMed] [Google Scholar]
  17. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954–62. [CrossRef] [PubMed] [Google Scholar]
  18. Aussy A, Fréret M, Gallay L, et al. The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol (Hoboken NJ) 2019; 71: 1360–70. [CrossRef] [Google Scholar]
  19. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14: 290–302. [CrossRef] [PubMed] [Google Scholar]
  20. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324–8. [CrossRef] [PubMed] [Google Scholar]
  21. Orandi AB, Dharnidharka VR, Al-Hammadi N, et al. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 2018; 16: 84. [Google Scholar]
  22. Yasin SA, Schutz PW, Deakin CT, et al. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 2019; 45: 495–512. [CrossRef] [PubMed] [Google Scholar]
  23. Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford) 2018; 57: 873–9. [CrossRef] [PubMed] [Google Scholar]
  24. Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 2017; 69: 1771–6. [CrossRef] [PubMed] [Google Scholar]
  25. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–6. [CrossRef] [PubMed] [Google Scholar]
  26. Hall JC, Casciola-Rosen L, Samedy LA, et al. anti-Mda5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307–15. [CrossRef] [PubMed] [Google Scholar]
  27. Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 2016; 186: 691–700. [CrossRef] [PubMed] [Google Scholar]
  28. Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68: 689–94. [CrossRef] [PubMed] [Google Scholar]
  29. Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132–7. [CrossRef] [PubMed] [Google Scholar]
  30. Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep [Internet]. 15 mars 2017 [cité 2 juin 2019]; 7. Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428032/. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.